ArticleClinical and translational radiation oncology2020
Daily adaptive radiotherapy for patients with prostate cancer using a high field MR-linac: Initial clinical experiences and assessment of delivered doses compared to a C-arm linac.
Article in Clinical and translational radiation oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it, 97 citations in OpenAlex.
- Guideline
- Daily adaptive 1.5 T MR-Linac image-guided re-irradiation for prostate cancer: an international retrospective experience.Clinical and translational radiation oncology · 2027Article
- Deep learning-enhanced image registration for accelerating daily adaptive magnetic resonance imaging-guided prostate radiotherapy.Physics and imaging in radiation oncology · 2026Article
- Clinical indicators for dose re-optimization in magnetic resonance-guided online adaptive radiotherapy for prostate cancer.Physics and imaging in radiation oncology · 2026Article
- Article
- A Dosimetric Comparison of the Accumulated Dose in Prostate SBRT for Non-Adaptive and Adaptive External Beam Radiotherapy.Cancers · 2026Article
- Survey data analysis of treatment planning methods in particle therapy facilities.Japanese journal of radiology · 2026Article
- Feasibility of reusing online-generated treatment plans for adaptive radiotherapy in prostate cancer.Physics and imaging in radiation oncology · 2026Article
- Intra-adaptational changes in online adaptive radiotherapy: from the ideal to the real dose.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2025Article
- Development of in-house software to process real-time cine magnetic resonance images acquired during 1.5 T MR-guided radiation therapy.Scientific reports · 2025Article
- Ultrahypofractionated radiotherapy for localised prostate cancer: The impact of daily MRI-guided adaptive radiotherapy on delivered dose.Clinical and translational radiation oncology · 2025Article
- New Approaches in Radiotherapy.Cancers · 2025Review
- Ultra-fast, one-click radiotherapy treatment planning outside a treatment planning system.Physics and imaging in radiation oncology · 2025Article
- Feasibility and time gain of implementing artificial intelligence-based delineation tools in daily magnetic resonance image-guided adaptive prostate cancer radiotherapy.Physics and imaging in radiation oncology · 2025Article
- Dealing with rectum motion during radiotherapy: How can we anticipate it?Technical innovations & patient support in radiation oncology · 2024Article
- Article
- Article
- Development of shielding evaluation and management program for O-ring type linear accelerators.Scientific reports · 2024Article
- MRI-guided radiotherapy in twenty fractions for localised prostate cancer; results from the MOMENTUM study.Clinical and translational radiation oncology · 2024Article
- Super-resolution neural networks improve the spatiotemporal resolution of adaptive MRI-guided radiation therapy.Communications medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
Abstract
introductionMR-guided adapted radiotherapy (MRgART) using a high field MR-linac has recently become available. We report the estimated delivered fractional dose of the first five prostate cancer patients treated at our centre using MRgART and compare this to C-Arm linac daily Image Guided Radiotherapy (IGRT).
methodsPatients were treated using adapted treatment plans shaped to their daily anatomy. The treatments were recalculated on an MR image acquired immediately prior to treatment delivery in order to estimate the delivered fractional dose. C-arm linac non-adapted VMAT treatment plans were recalculated on the same MR images to estimate the fractional dose that would have been delivered using conventional radiotherapy techniques using a daily IGRT protocol.
results95% and 93% of mandatory target coverage objectives and organ at risk dose constraints were achieved by MRgART and C-arm linac delivered dose estimates, respectively. Both delivery techniques were estimated to have achieved 98% of mandatory Organ At Risk (OAR) dose constraints whereas for the target clinical goals, 86% and 80% were achieved by MRgART and C-arm linac delivered dose estimates.
conclusionsProstate MRgART can be delivered using the a high field MR-linac. Radiotherapy performed on a C-arm linac offers a good solution for prostate cancer patients who present with favourable anatomy at the time of reference imaging and demonstrate stable anatomy throughout the course of their treatment. For patients with critical OARs abutting target volumes on their reference image we have demonstrated the potential for a target dose coverage improvement for MRgART compared to C-arm linac treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.